Urinary%20incontinence Management

Management

Monitoring

Consider immediate referral to a specialist in the following conditions:

Incontinence w/ abdominal &/or pelvic pain
Hematuria in the absence of an infection
Suspected fistula
Complex neurological conditions (eg Parkinson’s disease, spinal cord injury)
Abnormal findings (eg pelvic mass or symptomatic organ prolapse beyond the hymen)

Consider elective referral to a specialist in the following conditions:

Persistent symptoms after an adequate therapeutic trial
Uncertain diagnosis & lack of reasonable treatment plan
Significant increase in PVRV that does not resolve after treatment of possible precipitants (eg medications, stool impaction)
Prior pelvic surgery or pelvic irradiation
Desire for surgical treatment

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.